Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America. Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
How does Pentax Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pentax Medical's score of 41 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Pentax Medical reported total carbon emissions of approximately 788,000 kg CO2e. This figure includes 52,000 kg CO2e from Scope 1 emissions, 29,000 kg CO2e from Scope 2 emissions, and a significant 707,000 kg CO2e from Scope 3 emissions. In 2023, the company’s total emissions were about 866,000 kg CO2e, with the same Scope 1 and Scope 2 emissions as in 2025, while Scope 3 emissions were approximately 785,000 kg CO2e. The 2022 emissions were slightly higher at around 886,000 kg CO2e, with consistent Scope 1 and Scope 2 figures. Despite these emissions, Pentax Medical has not disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further clarity on their long-term sustainability strategies.
Access structured emissions data, company-specific emission factors, and source documents
2022 | 2023 | 2025 | |
---|---|---|---|
Scope 1 | 52,000 | 00,000 | 00,000 |
Scope 2 | 29,000 | 00,000 | 00,000 |
Scope 3 | 804,000 | 000,000 | 000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pentax Medical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.